Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease.
Sign Up to like & getrecommendations! Published in 2021 at "International journal of cardiology"
DOI: 10.1016/j.ijcard.2021.04.067
Abstract: Background The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial showed that rivaroxaban plus aspirin reduced major adverse cardiovascular events (MACE) in patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD).… read more here.
Keywords: risk; chads2; cha2ds2 vasc; vasc chads2 ... See more keywords